XML 41 R26.htm IDEA: XBRL DOCUMENT v3.24.3
ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2023
Oct. 31, 2024
Sep. 30, 2024
Aug. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Change in Accounting Estimate [Line Items]              
Letter of credit established as a deposit       $ 1,500      
Cash and cash equivalents $ 56,514 $ 56,514   39,201   $ 45,204 $ 100,444
Deferred revenues       774   $ 0  
Genentech, Inc. | License              
Change in Accounting Estimate [Line Items]              
Deferred revenues       $ 800      
Variable consideration amount         $ 1,900,000    
Contract with customer liability         $ 40,000    
Genentech, Inc. | License | Subsequent Event              
Change in Accounting Estimate [Line Items]              
Contract with customer liability     $ 10,000        
Kite Pharma Inc | Change In Agreement Estimate, March 2023              
Change in Accounting Estimate [Line Items]              
Increase in revenue   8,900          
Increase in net income   $ 8,900          
Increased earnings per share, basic (in dollars per share)   $ 0.05          
Increased earnings per share, diluted (in dollars per share)   0.05          
Kite Pharma Inc | Change In Agreement Estimate, September 2023              
Change in Accounting Estimate [Line Items]              
Increase in revenue 4,900            
Increase in net income $ 4,900            
Increased earnings per share, basic (in dollars per share) $ 0.03 0.03          
Increased earnings per share, diluted (in dollars per share) $ 0.03 $ 0.03